BeStock  
Stocks › Biotechnology › ELVN

Enliven Therapeutics ELVN

US equityMarket cap rank #2338Biotechnology
$46.53 +$0.12 (+0.26%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $46.53 0.00%
Open$46.05
Prev close$46.41
Day range$45.64 – $47.83
Volume933.6K
Market cap$3.42B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership118.0%+5.42 pts vs. prior quarter
Institutions holding260+9 vs. prior quarter
Insider trades (recent)15 buys / 35 sellsNet selling
Short interest14.05% of floatDays to cover 5.7 · as of 30 Oct 2026
Short-sale volume share23.3%5-day average of daily volume

Short-sale volume as % of daily volume

4%16%28%40%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$10.46M (8 inflow days, 12 outflow days).

Net flow by order size, last 20 sessions

−$10.3MSuper−$129.9KBig+$5.5MMid+$6.0MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 45.2% of shares outstanding.

Largest holders

  • FMR14.71%
  • OrbiMed Advisors LLC9.21%
  • Polar Capital Holdings Plc8.74%
  • BlackRock7.07%
  • Vestal Point Capital, LP5.44%
  • Commodore Capital LP4.45%
  • T. Rowe Price Group, Inc.4.35%
  • Vanguard Capital Management, LLC3.93%

By investor type

  • Mutual Fund67.39%
  • Hedge Fund32.50%
  • VC/PE Fund14.08%
  • Individual/Insider2.69%
  • Sovereign Wealth Fund1.88%
  • Public Company1.23%
  • Insurance Company0.45%
  • Government Pension Fund0.32%

Reported short interest has risen from 11.27% to 14.05% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Assenagon Asset Management S.A. Mutual Fund 2026/Q3 +847,399 1.6%
BlackRock Mutual Fund 2026/Q3 +846,877 7.1%
FMR Mutual Fund 2026/Q3 +802,714 14.7%
Westfield Capital Management Company, L.P. Mutual Fund 2026/Q3 +766,555 1.0%
State Street Global Advisors Mutual Fund 2026/Q3 +333,150 2.1%
Principal Global Investors, LLC Mutual Fund 2026/Q3 +332,238 0.5%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +324,107 3.9%
Geode Capital Management, LLC Mutual Fund 2026/Q3 +301,718 2.3%
FMR Mutual Fund 2026/Q3 +3,195,768 13.7%
T. Rowe Price Group, Inc. Mutual Fund 2026/Q3 +3,107,051 4.4%
Norges Bank Investment Management Sovereign Wealth Fund 2026/Q3 +1,382,333 1.9%
Polar Capital Holdings Plc Mutual Fund 2026/Q3 +1,364,703 8.7%
First Light Asset Management, LLC Mutual Fund 2026/Q3 +1,158,883 1.8%
Adage Capital Management, L.P. Hedge Fund 2026/Q3 +1,083,313 1.5%
Artal Group S.A. VC/PE Fund 2026/Q3 +1,028,185 2.4%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
29 Oct 2026 Lori Kunkel Independent Director Derivative Exercise and Retained +11,041 $18.30 52,925
18 Oct 2026 Helen Collins Chief Medical Officer Derivative Exercise and Sale -5,000 $38.47 25,000
18 Oct 2026 Benjamin Hohl CFO & Head of Corporate Development Derivative Exercise and Sale -6,018 $38.48 13,000
13 Oct 2026 Kristine Ball Director Other Derivative Acquisition +23,394 $39.28 23,394
30 Sep 2026 Scott Garland Director Derivative Exercise and Sale -13,000 $46.67 –
16 Sep 2026 Helen Collins Chief Medical Officer Derivative Exercise and Sale -5,000 $51.48 25,000
16 Sep 2026 Benjamin Hohl CFO & Head of Corporate Development Open Market Disposition -2,036 $51.49 13,000
16 Sep 2026 Benjamin Hohl CFO & Head of Corporate Development Derivative Exercise and Sale -3,982 $50.72 13,000
3 Sep 2026 Richard Heyman Former Independent Chairperson Intent to Sell (Form 144) -38,000 $59.29 –
16 Aug 2026 Helen Collins Chief Medical Officer Derivative Exercise and Sale -5,000 $59.35 25,000
16 Aug 2026 Benjamin Hohl CFO & Head of Corporate Development Automatic Disposition -6,018 $59.35 15,036
3 Aug 2026 Mika Derynck Independent Director Derivative Exercise and Sale -158,795 $60.21 –
16 Jul 2026 Helen Collins Chief Medical Officer Derivative Exercise and Sale -5,000 $53.92 25,000
16 Jul 2026 Benjamin Hohl CFO & Head of Corporate Development Automatic Disposition -4,946 $53.87 21,054
16 Jul 2026 Benjamin Hohl CFO & Head of Corporate Development Derivative Exercise and Sale -1,072 $52.32 21,054
5 Jul 2026 Lori Kunkel Independent Director Automatic Disposition -10,000 $50.84 41,884
21 Jun 2026 OrbiMed Advisors LLC Private Disposition -48,253 $45.00 6,774,507
21 Jun 2026 OrbiMed Advisors LLC Open Market Disposition -811,870 $45.38 6,774,507
16 Jun 2026 Helen Collins Chief Medical Officer Derivative Exercise and Sale -5,000 $44.74 25,000
16 Jun 2026 Benjamin Hohl CFO & Head of Corporate Development Derivative Exercise and Sale -6,018 $44.75 26,000

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 10,293,807 14.0% 5.7
15 Oct 2026 9,331,398 12.7% 7.5
30 Sep 2026 10,356,282 14.1% 5.5
15 Sep 2026 8,620,503 11.8% 9.0
31 Aug 2026 8,600,289 11.7% 11.1
14 Aug 2026 8,258,991 11.3% 6.3

Discussion

No comments yet — be the first to weigh in on ELVN.

Sign in to join the discussion.

Scroll to Top